Trial reportEuropean radiology experimental2025
SPIO-enhanced MRI for sentinel lymph node mapping in oral cancer: a prospective feasibility study.
Trial report in European radiology experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04803331 (Superparamagnetic Iron Oxide-enhanced Magnetic Resonance Imaging for Sentinel Lymph Node Identification in Oral Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Superparamagnetic Iron Oxide-enhanced Magnetic Resonance Imaging for Sentinel Lymph Node Identification in Oral Cancer: a Feasibility Study
Who cites it
1 citing paper in PubMed.
- Phase transfer studies of iron oxide nanoparticles: characterization based insights for applications.Nanoscale advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPatients with early-stage node-negative oral cancer undergo a sentinel lymph node biopsy (SLNB) or elective neck dissection under general anesthesia. A noninvasive imaging alternative would be of great interest. Superparamagnetic iron oxide (SPIO)-enhanced magnetic resonance imaging (MRI) can visualize draining lymph nodes and potentially metastases. We investigated the optimal combination of SPIO injection and T2*-weighted MRI settings to identify the sentinel lymph nodes (SLNs), the lymphatic drainage pattern, and possibly to detect metastatic SLNs. MATERIALS AND
methodsSPIO nanoparticles were injected submucosally around the primary tongue tumor in ten patients after routine SLNB imaging with indocyanine green-[
resultsOne mg of iron was deemed a suitable dose after two dose alterations. All 25 SLNs observed on SPECT/CT in eight patients were also identified on MRI. Including higher echelons, 55 lymph nodes were seen on SPECT/CT, while 107 lymph nodes were seen on MRI. Eighteen lymph nodes showed a mixture of partial MRI signal attenuation and retention, which, when compared to histopathology, made discrimination between metastatic and nonmetastatic lymph nodes solely based on MRI impossible.
conclusionSPIO-enhanced T2*-weighted MRI is suitable for mapping SLNs and lymphatic drainage pattern, showing significantly more lymph nodes compared to SPECT/CT. Discriminating metastatic from nonmetastatic nodes does not seem feasible after SPIO injection.
trial registrationClinicaltrials.gov NCT04803331. Registered 4 March 2021; https://clinicaltrials.gov/study/NCT04803331 . RELEVANCE STATEMENT: SPIO-enhanced MRI seems noninferior to the current method of SLN detection with technetium, with better anatomical detail than SPECT/CT: if proven comparable, SPIO-enhanced MRI could be considered a nonradioactive alternative with higher spatial resolution to define lymphatic drainage of tumors. KEY POINTS: The use of superparamagnetic iron oxide (SPIO)-enhanced MRI in head and neck cancer is underassessed. SPIO-enhanced MRI detects nodal drainage patterns comparably to SPECT/CT. SPIO-enhanced MRI does not discriminate lymph node metastases from false positives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.